{
  "source": "PA-Notification-Orfadin.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1185-10\nProgram Prior Authorization/Notification\nMedication Orfadin® (nitisinone)\nP&T Approval Date 5/2016, 5/2017, 5/2018, 5/2019, 5/2020, 5/2021, 5/2022, 5/2023,\n5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nOrfadin (nitisinone) is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the\ntreatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in\ncombination with dietary restriction of tyrosine and phenylalanine.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Orfadin will be approved based on both of the following criteria:\na. Diagnosis of hereditary tyrosinemia type 1\n-AND-\nb. Orfadin is being used as an adjunct to diet modification\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Orfadin will be approved based on the following criterion:\na. Patient shows evidence of positive clinical response (e.g., decrease in\nurinary/plasma succinylacetone and alpha-1-microglobulin levels) while on Orfadin\ntherapy\nAuthorization will be issued for 24 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\n© 2025 UnitedHealthcare Services, Inc.\n1\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Orfadin [prescribing information]. Waltham, MA. Sobi, Inc. November 2021.\nProgram Prior Authorization/Notification – Orfadin (nitisinone) capsules, for\noral use, and oral suspension\nChange Control\n5/2016 New program\n5/2017 Annual review. Added criteria to align with package insert (",
    "rior Authorization/Notification – Orfadin (nitisinone) capsules, for\noral use, and oral suspension\nChange Control\n5/2016 New program\n5/2017 Annual review. Added criteria to align with package insert (used as\nadjunct to diet modification). Updated reauthorization verbiage to align\nwith standard verbiage (patient shows evidence of). Updated\nreferences.\n5/2018 Annual review. Updated references.\n5/2019 Annual review. No changes to coverage criteria.\n5/2020 Annual review with no changes to clinical criteria. Updated reference.\n5/2021 Annual review. No changes to coverage criteria.\n5/2022 Annual review. No changes to coverage criteria.\n5/2023 Annual review. Added state mandate footnote. Updated reference.\n5/2024 Annual review. No changes to clinical criteria.\n5/2025 Annual review. No changes to clinical criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}